Skip to main content
Journal ArticleOPEN ACCESS

Bothe combination of TLR2 and TLR4 agonists promotes the immunogenicity of dendritic cell/cancer cell fusions

OncoImmunology (2013) 2(7)
DOI: 10.4161/onci.24660
1Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The induction of antitumor immune responses by dendritic cell (DC)/tumor cell fusions can be modulated by their activation status. Our recent work reveals that the combination of Toll-like receptor 2 (TLR2) and TLR4 agonists promotes the immunogenicity of DC/tumor cell fusions, allowing them to overcome the immunosuppressive effects of transforming growth factor ß1 ©2013 Landes Bioscience.

Author supplied keywords

Cite

CITATION STYLE

APA

Koido, S., Homma, S., Okamoto, M., Namiki, Y., Takakura, K., Uchiyama, K., … Tajiri, H. (2013). Bothe combination of TLR2 and TLR4 agonists promotes the immunogenicity of dendritic cell/cancer cell fusions. OncoImmunology, 2(7). https://doi.org/10.4161/onci.24660

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free